EU seeks information from Novartis over skin-drug patent
Novartis is subject to a “preliminary investigation” by EU antitrust authorities over treatments for a skin condition, the European Commission has confirmed. The EU authority is cooperating with a sister regulator...To view the full article, register now.
Already a subscriber? Click here to view full article